Characteristics and clinical significance of cutaneous immune-related adverse events during atezolizumab therapy: An individual participant data meta-analysis
Indian Journal of Dermatology, Venereology and Leprology · 17.11.2025 · 1-10
DOI: 10.25259/ijdvl_1043_2025 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, online erschienen am 17.11.2025. Verfasst von Rentao Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
The spectrum of cutaneous immune-related adverse events (cirAEs) has been described, and the occurrence of cirAEs may be associated with improved survival. However, the accuracy of these findings is limited by inconsistent classification.
Aim
This study was designed to determine the type, incidence, and timing of cirAEs and their impacts on survival in cancer patients treated with atezolizumab by using the Medical Dictionary for Regulatory Activities (MedDRA) classification.
Methods
The Vivli platform was used to search for randomised controlled trials (RCTs) on atezolizumab. Patients with individual patient data (IPD) were enrolled in the study. Both 1-stage pooled analysis and 2-stage meta-analysis were used to estimate the survival outcomes of the occurrence of cirAEs during atezolizumab therapy, as well as their types, incidences, and timing.
Results
Fifteen RCTs having IPDs of 5870 patients were enrolled in this study. The incidence was 27.5% in this study, with rash/eruption/exanthem (83.9%) being the most frequent cirAEs. The earliest types to occur were alopecia. The occurrence of cirAE was an independent protective factor for both overall survival (OS, hazard ratio [HR]=0.40-0.72) and progression-free survival (PFS, HR=0.52-0.84). However, with respect to specific types, urticaria, erythema, alopecia, etc. were found to be independent protective factors for OS, whereas dry skin, purpura, dermatitis/eczema, etc. were found to be independent protective factors for PFS. Regarding the impact of management and outcomes, cirAE following medical treatment was an independent protective factor for both OS (HR=0.731, 0.622-0.859, P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China.
Zitieren
APA
Yu, R., Wu, Q., Zeng, Q., Pan, Y., Chen, X., Hu, L., & Chen, A. (2025). Characteristics and clinical significance of cutaneous immune-related adverse events during atezolizumab therapy: An individual participant data meta-analysis. Indian Journal of Dermatology, Venereology and Leprology, 0, 1-10. https://doi.org/10.25259/ijdvl_1043_2025
Vancouver
Yu R, Wu Q, Zeng Q, Pan Y, Chen X, Hu L, et al. Characteristics and clinical significance of cutaneous immune-related adverse events during atezolizumab therapy: An individual participant data meta-analysis. Indian Journal of Dermatology, Venereology and Leprology. 2025;0:1-10. doi:10.25259/ijdvl_1043_2025
BibTeX
@article{Yu2025,
author = {Yu, Rentao and Wu, Qian and Zeng, Qianwen and Pan, Yun and Chen, Xin and Hu, Li and Chen, Aijun},
title = {Characteristics and clinical significance of cutaneous immune-related adverse events during atezolizumab therapy: An individual participant data meta-analysis},
journal = {Indian Journal of Dermatology, Venereology and Leprology},
year = {2025},
volume = {0},
pages = {1--10},
doi = {10.25259/ijdvl_1043_2025}
}
EUVIMED